TABLE 5.

Results of targeted lung denervation

	RCT	Subjects	Dose	Time point	Result	First author, year [reference]
Quality of life
SGRQ total score absolute change	No	10	20 W	1 year	−11.1±9.1	Slebos, 2015 [35]
	No	10	15 W	1 year	−0.9±8.6	Slebos, 2015 [35]
	No	15	15 W	1 year	−1.85±20.8	Valipour, 2018 [38]
	Yes	15	32 W	1 year	−7.5±10.3	Valipour, 2019 [39]
	Yes	15	29 W	1 year	−1.9±12.5	Valipour, 2019 [39]
	No	16	32 W	1 year	−6.1±21#	Valipour, 2019 [39]
	Yes	82	26/32 W	1 year	No sign. difference between treatment group and SoC group	Slebos, 2019 [40]
Chronic bronchitis symptoms	Not reported
Lung function
FEV1 % change	No	10	20 W	1 year	11.6±32.3	Slebos, 2015 [35]
	No	10	15 W	1 year	0.02±15.1	Slebos, 2015 [35]
	No	15	15 W	1 year	40.3±42.1	Valipour, 2018 [38]
FEV1 mL change	Yes	15	32 W	1 year	94.2±228	Valipour, 2019 [39]
	Yes	15	29 W	1 year	57±82	Valipour, 2019 [39]
	No	16	32 W	1 year	34±174#	Valipour, 2019 [39]
	Yes	82	26/32 W	1 year	No sign. difference between treatment group and SoC group	Slebos, 2019 [40]
Exercise capacity
6MWD m absolute change	No	10	20 W	1 year	24.2±45.6	Slebos, 2015 [35]
	No	10	15 W	1 year	−9.3±70.6	Slebos, 2015 [35]
	No	15	15 W	1 year	53.7±74.4	Valipour, 2018 [38]
Cycle ergometry endurance time	Yes	82	26/32 W	1 year	No sign. difference between treatment group and SoC group	Slebos, 2019 [40]
Other
Inflammation markers (CCl4 protein, CXCL8 gene, TGF-β gene)	No	7	?	30 days	Significant decrease in all markers (p<0.05)	Kistemaker, 2015 [36]

Data are presented as n or mean±sd. Statistically significant values (p<0.05) are presented in bold. RCT: randomised controlled trial; SGRQ: St George's Respiratory Questionnaire; FEV₁: forced expiratory volume in 1 s; 6MWD: 6-min walk distance; TGF: transforming growth factor; SoC: standard of care. ^#: p-values were not reported.